^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
RG6440
i
Other names: RG6440, SOF10, RO7496353, RG 6440, RO 7496353, SOF 10, RG-6440, RO-7496353, SOF-10
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Roche
Drug class:
TGF-β1 inhibitor
Related drugs:
5ms
A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010 (clinicaltrials.gov)
P1, N=102, Active, not recruiting, Genentech, Inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026
Trial completion date • Trial primary completion date • Checkpoint inhibition
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
1year
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=120, Active, not recruiting, Genentech, Inc. | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy • Checkpoint inhibition • Metastases
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
over2years
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=120, Not yet recruiting, Genentech, Inc.
New P1 trial • Combination therapy • Checkpoint inhibition • Metastases
|
Opdivo (nivolumab) • Tecentriq (atezolizumab) • gemcitabine • capecitabine • albumin-bound paclitaxel • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • RG6440
Share via
